Combining atezolizumab and bevacizumab with stereotactic body radiotherapy for advanced liver cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the efficacy and safety of a combination therapy using atezolizumab and bevacizumab alongside stereotactic body radiotherapy (SBRT) in patients with advanced hepatocellular carcinoma. Participants will receive SBRT for one or more primary cancers or metastatic lesions within two months before or after starting the combination therapy. The study will assess treatment response rates and monitor adverse events through a series of scheduled visits that include medical evaluations and quality of life questionnaires.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 19 to 80 years old
2. Liver function Child-Pugh class A
3. ECOG 0-1
4. Patient clinically or pathologically diagnosed with hepatocellular carcinoma
5. Advanced hepatocellular carcinoma that is inoperable
6. Satisfies the dose limits for normal organs and lesions of an appropriate size to be included in the scope of radiotherapy.

Exclusion Criteria:

1. Brain metastases
2. Have a history of malignancy other than hepatocellular carcinoma within the last 5 years (except for malignancies with little risk of metastasis or death, e.g., adequately treated cervical carcinoma in situ, non-melanoma skin cancer, localized prostate cancer, tubular carcinoma in situ, or stage 1 uterine cancer.)
3. Subjects with a high probability of untreated gastric or esophageal varices or bleeding
4. Serious uncontrolled medical comorbidities
5. History of liver transplant surgery
6. Autoimmune liver disease

Where it's running

• Yongin Severance Hospital
  Yongin-si, South Korea Recruiting

Study contacts

• Principal investigator: Hwakyung BYUN, Phd — Severance Hospital
• Study coordinator: Hwakyung BYUN, Phd
• Email: hkbyun05@yuhs.ac
• Phone: 007981072098955

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining dTACE-HAIC with Bevacizumab and Atezolizumab for treating large liver cancer

  This study is testing a new combination treatment for people with large liver cancer to see if it works better than current options for those who can't have surgery.

  Recruiting Sun Yat-sen University · Beijing, None Selected · NCT06609863

• Blood biomarkers to predict response to atezolizumab plus bevacizumab in hepatocellular carcinoma

  This study tests whether blood-based biomarkers can predict which patients with advanced liver cancer will respond to first-line atezolizumab plus bevacizumab.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07734857

• AI system to predict response to Atezolizumab-Bevacizumab in unresectable liver cancer

  This study looks at whether an artificial intelligence tool can predict how patients with unresectable hepatocellular carcinoma will respond to atezolizumab-bevacizumab.

  Recruiting First Affiliated Hospital of Wenzhou Medical University · Wenzhou, Zhejiang · NCT07495735

• TIPS benefits for people with hepatocellular carcinoma taking Tecentriq (atezolizumab) plus Avastin (bevacizumab) as first-line therapy.

  This study will try to see if placing a TIPS device helps people with advanced or unresectable hepatocellular carcinoma who are starting first-line treatment with Tecentriq plus Avastin.

  Recruiting Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Düsseldorf, North Rhine-Westphalia · NCT07365930

• Bevacizumab followed by atezolizumab versus both together for advanced hepatocellular carcinoma with MASLD

  This test will see if giving bevacizumab first and then atezolizumab works better than giving both at the same time for adults with advanced hepatocellular carcinoma and metabolic-associated steatotic liver disease (MASLD).

  Recruiting Phase 2/3 Eastern Hepatobiliary Surgery Hospital · Shanghai, Shanghai Municipality · NCT07285850

• Using fecal microbiota transplantation to try to restore response to atezolizumab and bevacizumab in people with unresectable hepatocellular carcinoma.

  This will try whether giving a fecal microbiota transplant and then restarting atezolizumab plus bevacizumab can restore treatment response in adults with unresectable HCC who progressed early on those drugs.

  Recruiting Phase 2 IRCCS Azienda Ospedaliero-Universitaria di Bologna · Bologna, BO · NCT07276100

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.